poisar

Stocks · News reference

Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate

Aug 4, 2026, 8:03 PMBenzinga Newsdesk

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.62 by 41.94 percent. This is a 73.17 percent decrease over earnings of $3.28 per share

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RIGL
Source
benzinga
Observed
Aug 4, 2026, 8:03 PM
Checked
Aug 4, 2026, 8:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Aug 13, 2026, 12:13 PMBenzinga Newsdesk

    Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription

    VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to selectively

    Read original at benzinga
    RIGL